Dynavax Technologies (DVAX) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Dynavax Technologies Corporation  (NASDAQ: DVAX)
 

Dynavax Technologies Growth Comparisons

Select each growth Category to receive further Information





DVAX Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 17.67 % 10.18 % 8.72 % 7.86 %
Q / Q Revenue Growth (Q3 MRQ) -0.59 % 5.72 % 4.73 % 4.58 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 26.73 % 7.47 % 5.86 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) 4.5 % 1.56 % 1.72 % 1.97 %
Revenue 5 Year Average Growth 51.08 % 14.14 % 10.99 % 7.73 %


DVAX's Growth Comparisons in III. Quarter 2025




Dynavax Technologies's 17.67% year on year Revenue growth, has slowed-down in the third quarter 2025 to 95 millions, but outperforms the 10.18% rise in the Major Pharmaceutical Preparations industry, and 8.72% growth in the Healthcare sector. Above the average sales gains in the Healthcare and in the Major Pharmaceutical Preparations industry, helped to elevate overall market growth to 7.86%.

Top-line fell by -0.59% from the second quarter. Average annual sales growth for Dynavax Technologies is 51.08%, while S & P 500's average yearly sales increase is 7.73%, including only Businesses with the third quarter 2025 financial results.

DVAX Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Reportable Segments
17.67 %
-0.59 %
U S
17.47 %
1.2 %
Non U S
731.82 %
-90.24 %
Product revenue net
13.37 %
-2.09 %
Product revenue net U S
13.37 %
-0.33 %
HEPLISAV-B
13.37 %
-2.09 %
HEPLISAV-B U S
13.37 %
-0.33 %
Other revenue
283.04 %
37.87 %
Other revenue U S
275.22 %
42.87 %
Other revenue Non U S
731.82 %
-27.67 %
Total
17.67 %
-0.59 %


Growth Rates of DVAX's Income in the third quarter 2025


DVAX Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) 110.98 % 34.93 % 27.6 % 14.52 %
Sequential Operating Income Change (Q3 MRQ) 47.42 % 12.92 % 11.97 % 7.3 %
Y / Y Operating Income Growth (Q3 TTM) - 95.1 % 50.83 % 6.44 %
Sequential Operating Income Growth (Q3 TTM) - 14.22 % 9.78 % 3.54 %
Operating Income 5 Year Avg. Change - 0.11 % -0.96 % 9 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) 53.05 % 52.04 % 23.61 % 18.96 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) 43.83 % 14.65 % -14.29 % 3.03 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) - - 56.96 % 14.26 %
Sequential Income from Cont. Ops. Change (Q3 TTM) - - 13.6 % 4.45 %
Income from Cont. Ops. 5 Year Avg. Change - -18.69 % -17.93 % 8.34 %

DVAX Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) 53.05 % 55.45 % 13.05 % 18.25 %
Q / Q Net Income Growth (Q3 MRQ) 43.83 % 15.99 % 13.24 % 3.11 %
Y / Y Net Income Change (Q3 TTM) - 174.88 % 90.25 % 15.08 %
Sequential Net Income Change (Q3 TTM) - 18.53 % 9.39 % 4.28 %
Net Income 5 Year Avg. Growth - 14.51 % 6.2 % 9.47 %

DVAX's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) 76.92 % 24.18 % 23.61 % 18.96 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) 43.75 % -9.75 % -14.29 % 3.03 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) - - - -47.94 %
EPS from Cont. Ops. 5 Year Avg. Growth - -29.42 % -17.93 % 8.34 %



DVAX EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) 75 % 26.96 % 13.05 % 8.34 %
Q / Q EPS Net Growth (Q3 MRQ) 50 % -8.69 % 13.24 % 3.11 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - -66.9 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) - - - -47.94 %
EPS Net 5 Year Avg. Change - 14.51 % 6.2 % 9.47 %



Dynavax Technologies showed respectable 75% year on year rise of EPS in the third quarter, comparing favorably to the 26.96% improvement in the Major Pharmaceutical Preparations industry, and 13.05% improvement in the Healthcare sector. Comparing the third quarter income per share growth, both Major Pharmaceutical Preparations industry and Dynavax Technologies Corporation outperformed 18.25% overall market increase.

The bottom-line grew by 50% from the second quarter. Average yearly income per share growth for Dynavax Technologies is 51.08%, while S & P 500's average annual income per share increase is 9.47% over the five years, including only Businesses with the third quarter 2025 earnings reports.

DVAX Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) 79.86 % 12.15 % 24.37 % 73.68 %
Sequential Free Cash Flow Change (Q3 MRQ) 48.29 % 161.37 % 155.47 % 27.4 %
Y / Y Free Cash Flow Change (Q3 TTM) 255.26 % 33.95 % 32.2 % 19.32 %
Sequential Free Cash Flow Change (Q3 TTM) 21.9 % 10.62 % 12.58 % 12.94 %
Free Cash Flow 5 Year Avg. Change - 9.45 % 6.34 % 10.76 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) 793.82 % - - -
Sequential Net Cash Flow Change (Q3 MRQ) 28.99 % - - -
Y / Y Net Cash Flow Change (Q3 TTM) - -13.02 % 147.63 % -
Sequential Net Cash Flow Change (Q3 TTM) - 60.43 % 448.55 % -
Net Cash Flow 5 Year Avg. Change - -8.21 % -1.7 % -32.35 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) -8.1 % 24.09 % 13.37 % 22.12 %
Sequential Capital Expenditures Change (Q3 MRQ) -14.81 % 18.9 % 11.28 % 8.66 %
Y / Y Capital Expenditures Change (Q3 TTM) 119.6 % 13.48 % 6.43 % 22.98 %
Sequential Capital Expenditures Change (Q3 TTM) -1.07 % 4.83 % 2.52 % 5.32 %
Capital Expenditures 5 Year Avg. Change -22.28 % 10.12 % 8.7 % 10.66 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.